F
Live / Registered — Registered (as of 10 Mar 2020)
What this means for you
Registered since 10 Mar 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88028459
- Registration number
- 6008689
- Mark type
- Word mark
- Filed
- 06 Jul 2018
- Published for opposition
- 18 Jun 2019
- Registered
- 10 Mar 2020
- Attorney of record
- Rebecca E. McDougall
Goods and services
- Class 001 — Chemicals: Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
- Class 005 — Pharmaceuticals: Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
- Class 009 — Scientific and electric apparatus: Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
- Class 042 — Scientific and technological services: Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
Owner
- Factor Bioscience LLC, Cambridge, MA, US
- Factor Bioscience LLC, Cambridge, MA, US
- Factor Bioscience LLC, Cambridge, MA, US
Prosecution history
- 09 Sept 2026 — TEAS SECTION 8 & 15 RECEIVED
- 10 Mar 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 10 Mar 2020 — REGISTERED-PRINCIPAL REGISTER
- 05 Feb 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 04 Feb 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 29 Dec 2019 — STATEMENT OF USE PROCESSING COMPLETE
- 18 Dec 2019 — USE AMENDMENT FILED
- 29 Dec 2019 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Dec 2019 — TEAS STATEMENT OF USE RECEIVED
- 13 Aug 2019 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 18 Jun 2019 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 18 Jun 2019 — PUBLISHED FOR OPPOSITION
- 29 May 2019 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 10 May 2019 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 09 May 2019 — EXAMINER'S AMENDMENT ENTERED